Toca 5 Clinical Trial The Toca 5 trial is for patients who are planning to undergo removal of a recurrent glioblastoma or anaplastic astrocytoma tumor.
The Toca 5 trial is an international, Phase 2/3 randomized, open-label study of Toca 511, a Retroviral Replicating Vector & Toca FC versus standard of care.
A patient may qualify for this study if the patient:
- has glioblastoma or anaplastic astrocytoma at 1st or 2nd recurrence
- has had prior surgery, radiation and chemotherapy
- is between 18 years old and 75 years old
For more information including additional entry criteria please contact the ANS Brain Tumor Center at (973) 285-7816. Additional information can also be found on www.clinicaltrials.gov.
This study is being sponsored by Tocagen. More information about Tocagen and Toca 511 & Toca FC are available at their website: www.tocagen.com.
Toca 511 & Toca FC are investigational products. An investigational product is one that has not been proven to be safe and effective for this use and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.